Douglas J Ward

Summary

Publications

  1. ncbi request reprint Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles
    Douglas J Ward
    Dupont Circle Physicians Group, 1737 20th Street NW, Washington, DC 20009, USA
    AIDS Patient Care STDS 20:542-8. 2006
  2. ncbi request reprint Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification
    Peter A Sklar
    Division of Infectious Dieseases, George Washington university and Dupont Circle Physicians Group, Washington, DC, USA
    AIDS 16:2035-41. 2002
  3. ncbi request reprint Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients
    Kenneth A Lichtenstein
    Rose Medical Center, Unviersity of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    J Acquir Immune Defic Syndr 32:48-56. 2003
  4. ncbi request reprint Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003
    Pragna Patel
    Centers for Disease Control and Prevention, Emory University, and Northrop Grumman Information Technology, Atlanta, Georgia 30333, USA
    Ann Intern Med 148:728-36. 2008
  5. doi request reprint Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
    Tae Wook Chun
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 197:714-20. 2008
  6. ncbi request reprint Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
    Sharon L Walmsley
    Toronto General Hospital, University of Toronto, Toronto, Canada
    AIDS 21:2245-8. 2007
  7. ncbi request reprint Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006
    Jacob P Lalezari
    Quest Clinical Research, Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Antimicrob Chemother 60:170-4. 2007
  8. ncbi request reprint Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection
    Peter Ruane
    Private Practice, Los Angeles, California, USA
    HIV Clin Trials 7:229-36. 2006
  9. ncbi request reprint Protease inhibitors and cardiovascular outcomes in patients with HIV-1
    Scott D Holmberg
    Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Lancet 360:1747-8. 2002
  10. pmc HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir
    Tae Wook Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 115:3250-5. 2005

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles
    Douglas J Ward
    Dupont Circle Physicians Group, 1737 20th Street NW, Washington, DC 20009, USA
    AIDS Patient Care STDS 20:542-8. 2006
    ....
  2. ncbi request reprint Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification
    Peter A Sklar
    Division of Infectious Dieseases, George Washington university and Dupont Circle Physicians Group, Washington, DC, USA
    AIDS 16:2035-41. 2002
    ..To examine the prevalence and clinical correlates of subsequently measurable viremia in HIV-infected patients who have achieved viral suppression below the limits of quantification (< 50 copies/ml)...
  3. ncbi request reprint Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients
    Kenneth A Lichtenstein
    Rose Medical Center, Unviersity of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    J Acquir Immune Defic Syndr 32:48-56. 2003
    ..Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy...
  4. ncbi request reprint Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003
    Pragna Patel
    Centers for Disease Control and Prevention, Emory University, and Northrop Grumman Information Technology, Atlanta, Georgia 30333, USA
    Ann Intern Med 148:728-36. 2008
    ..Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population...
  5. doi request reprint Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
    Tae Wook Chun
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 197:714-20. 2008
    ....
  6. ncbi request reprint Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
    Sharon L Walmsley
    Toronto General Hospital, University of Toronto, Toronto, Canada
    AIDS 21:2245-8. 2007
    ..Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir...
  7. ncbi request reprint Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006
    Jacob P Lalezari
    Quest Clinical Research, Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Antimicrob Chemother 60:170-4. 2007
    ..10-fold more potent than the recently marketed PI, darunavir...
  8. ncbi request reprint Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection
    Peter Ruane
    Private Practice, Los Angeles, California, USA
    HIV Clin Trials 7:229-36. 2006
    ....
  9. ncbi request reprint Protease inhibitors and cardiovascular outcomes in patients with HIV-1
    Scott D Holmberg
    Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Lancet 360:1747-8. 2002
    ..5, 0.9-47.8). Our findings suggest that, although infrequent, use of protease inhibitors is associated with increased risk of myocardial infarction in patients with HIV-1...
  10. pmc HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir
    Tae Wook Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 115:3250-5. 2005
    ..Such events may allow continual replenishment of the CD4+ T cell reservoir and resetting of the half-life of the latently infected, resting CD4+ T cells despite prolonged periods of aviremia...
  11. ncbi request reprint Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine
    J Tyler Lonergan
    Department of Medicine, Owen Clinic University of California at San Diego Medical Center, 92103, USA
    J Acquir Immune Defic Syndr 36:935-42. 2004
    ....
  12. ncbi request reprint Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study
    Grace A McComsey
    Case Western Reserve, Cleveland, Ohio, USA
    Clin Infect Dis 38:263-70. 2004
    ..HIV suppression was maintained over the study period. In conclusion, replacing stavudine with abacavir or zidovudine resulted in improvement in stavudine-induced lipoatrophy...
  13. doi request reprint Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005
    Kate Buchacz
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS 22:1345-54. 2008
    ..To assess temporal trends in the rates of hospitalizations and associated diagnoses among HIV-infected patients before and during the era of highly active antiretroviral therapy...